ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - rosuvastatin as calcium 10 mg - tablets - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.

ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - rosuvastatin as calcium 20 mg - tablets - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.

ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - rosuvastatin as calcium 40 mg - tablets - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.

ישראל - עברית - Ministry of Health

medison pharma ltd - bezafibrate - טבליות עם שחרור מושהה - bezafibrate 400 mg - bezafibrate - bezafibrate - hyperlipidemia of types iia, iib, iii, iv, v in patients where diet alone is insufficient.

ישראל - עברית - Ministry of Health

cts chemical industries ltd, israel - ciprofibrate - קפסולות - ciprofibrate 100 mg - ciprofibrate - ciprofibrate - for the treatment of primary hyperlipidaemia resistant to appropriate dietary management, including hypercholesterolaemia, hypertriglyceridaemia and combined hyperlipidaemia.

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd, israel - omega-3 acid ethyl esters - קפסולות - omega-3 acid ethyl esters 1000 mg - omega-3-triglycerides - omega-3-triglycerides - post myocardial infarction: adjuvant treatment in secondary prevention after myocardial infarction, in addition to other standard therapy (e.g. statins, antiplatelet drugs, betablockers, ace inhibitors). hypertriglyceridaemia: endogenous hypertriglyceridaemia as a supplement to diet when dietary measures alone are insufficient to produce an adequate response: - type iv hypertriglyceridaemia. - type iib/iii hypertriglyceridaemia in combination with statin, when control of triglycerides by statins is insufficient.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - ezetimibe 10 mg - tablets - ezetimibe - primary hypercholesterolemia: ezetrol administered with an hmg-coa reductase inhibitor (statin) or alone are indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. homozygous familial hypercholesterolemia (hofh): ezetrol administered with a statin are indicated for use in patients with hofh.patients may also receive adjunctive treatments (e.g. ldl apheresis).homozygous sitosterolemia (phytosterolemia): ezetrol are indicated for use in patients with homozygous familial sitosterolemia.

ישראל - עברית - Ministry of Health

organon pharma israel ltd., israel - ezetimibe - טבליה - ezetimibe 10 mg - ezetimibe - ezetimibe - primary hypercholesterolemia: ezetrol administered with an hmg-coa reductase inhibitor (statin) or alone are indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. homozygous familial hypercholesterolemia (hofh): ezetrol administered with a statin are indicated for use in patients with hofh.patients may also receive adjunctive treatments (e.g. ldl apheresis).homozygous sitosterolemia (phytosterolemia): ezetrol are indicated for use in patients with homozygous familial sitosterolemia.

ישראל - עברית - Ministry of Health

unipharm ltd, israel - bezafibrate - טבליה - bezafibrate 200 mg - fibrates - reduction of elevated blood levels of cholesterol and triglycerides.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 40 mg - hmg coa reductase inhibitors - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa